The National Institutes of Health system for enhancing the science, safety, and ethics of recombinant DNA research.
Oversight of recombinant DNA research by the National Institutes of Health (NIH) is predicated on ethical and scientific responsibilities that are akin, in many ways, to those that pertain to the oversight of animal research. The NIH system of oversight, which originated more than 25 years ago, is managed by the NIH Office of Biotechnology Activities (OBA), which uses various tools to fulfill its oversight responsibilities. These tools include the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) and the Recombinant DNA Advisory Committee. The OBA also undertakes special initiatives to promote the analysis and dissemination of information key to our understanding of recombinant DNA, and in particular, human gene transfer research. These initiatives include a new query-capable database, an analytical board of scientific and medical experts, and conferences and symposia on timely scientific, safety, and policy issues. Veterinary scientists can play an important role in the oversight of recombinant DNA research and in enhancing our understanding of the many safety and scientific dimensions of the field. These roles include developing appropriate animal models, reporting key safety data, enhancing institutional biosafety review, and promoting compliance with the NIH Guidelines.
Shipp
Allan C
AC
Office of Biotechnology Activities, National Institutes of Health, Bethesda, Maryland 20892, USA.
Patterson
Amy P
AP
D000827:Animal Welfare; D000818:Animals; D003264:Containment of Biohazards / Q000592:standards; D004274:DNA, Recombinant; D004989:Ethics; D017408:Guidelines as Topic; D009316:National Institutes of Health (U.S.) / Q000458:organization & administration*; D011640:Public Policy; D012449:Safety; D012926:Social Control, Formal; D014481:United States
D004274:DNA, Recombinant